Phenotypes Associated with This Genotype

Genotype
MGI:5521543

• Allelic Composition: Tg(EmuSR-tTa)83Bop/0; Tg(IghMyc)22Bri/0; Tg(tetO-RNAi:Trp53)ASlowe/0
• Genetic Background: involves: C57BL * C57BL/6 * FVB/N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:123006 )

• mutants become moribund without a large peripheral tumor burden, with a median survival of 82 days

neoplasm

increased lymphoma incidence ( J:123006 )

• mutants develop lymphoma, with latency of tumorigenesis reduced compared to single Tg(IghMyc)22Bri/0 mice

• lymphoma-bearing mice treated with doxycycline at the onset of paralysis regain full movement within 2 days of doxycycline treatment, show tumor involution, and live for a further 24-64 days before tumors relapse

growth/size/body

enlarged spleen ( J:123006 )

• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver

hematopoietic system

enlarged spleen ( J:123006 )

• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver

immune system

enlarged spleen ( J:123006 )

• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver

behavior/neurological

hindlimb paralysis ( J:123006 )

• partial hind leg paralysis is seen in some mutants, most likely attributed to lymphoma